Work

Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-198660

Authors: Matthew Matasar, Katherine L Rosettie, Shih-Wen Lin, Mei Wu, Esprit Ma

Institutions: Rutgers, The State University of New Jersey, Rutgers Cancer Institute, Genentech

Language: English

Topic: Economic and Financial Impacts of Cancer

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405038390

Cites:

Cited by: 1

Related to: 10